| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Bayesian framework to quantify survival uncertainty
|
Loya, H.
|
|
|
30 |
S7 |
p. vii32-vii33
|
artikel
|
| 2 |
ABCB7 is a gatekeeper of both programmed cell death, apoptotic and non-apoptotic cell death
|
Kim, J.Y.
|
|
|
30 |
S7 |
p. vii28
|
artikel
|
| 3 |
A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)
|
Enrico, D.H.
|
|
|
30 |
S7 |
p. vii8-vii9
|
artikel
|
| 4 |
AI oncology algorithm-based prioritisation of EGFR inhibitors in case of rare EGFR mutations
|
Tihanyi, D.
|
|
|
30 |
S7 |
p. vii30
|
artikel
|
| 5 |
A laboratory assay for improved prediction of drug responses in acute myeloid leukaemia cells
|
Aleem, E.
|
|
|
30 |
S7 |
p. vii20-vii21
|
artikel
|
| 6 |
A new quercetin glycoside enhances TNBC immunological profile through TP53/miR-155/MICA/ULBP2
|
Abdel-Latif, M.
|
|
|
30 |
S7 |
p. vii7-vii8
|
artikel
|
| 7 |
An exceptional response to immunotherapy doublet in combined hepatocellular carcinoma-cholangiocarcinoma
|
Tahover, E.
|
|
|
30 |
S7 |
p. vii15
|
artikel
|
| 8 |
Anti-breast cancer activity of 7-α-hydroxyfrullanolide triggered G2/M arrest and apoptotic induction of triple negative breast cancer cell line, revealed by proteomics
|
Chimplee, S.
|
|
|
30 |
S7 |
p. vii12
|
artikel
|
| 9 |
Anti-osteolytic use to prevent skeletal related events in solid tumour bone metastases
|
Woodard, C.R.
|
|
|
30 |
S7 |
p. vii30-vii31
|
artikel
|
| 10 |
Application of variant interpretation software to decipher pathogenicity of mutations for a molecular tumour board (MTB)
|
Southam, S.
|
|
|
30 |
S7 |
p. vii10
|
artikel
|
| 11 |
Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort
|
Vinches, M.
|
|
|
30 |
S7 |
p. vii24
|
artikel
|
| 12 |
A retrospective analysis of 66 colorectal cancer cases from Guy’s and St Thomas’ (GSTT) Molecular Tumour Board
|
Kapiris, M.
|
|
|
30 |
S7 |
p. vii9
|
artikel
|
| 13 |
Artemisia absinthium nanoparticles induce apoptosis in breast cancer cells via inhibiting vesicular trafficking related proteins
|
Mughees, M.
|
|
|
30 |
S7 |
p. vii9
|
artikel
|
| 14 |
A seven-gene methylation markers panel: An epigenetic predictor of neoadjuvant chemotherapy sensitivity in triple-negative breast cancer
|
Sigin, V.O.
|
|
|
30 |
S7 |
p. vii17-vii18
|
artikel
|
| 15 |
Assessing melanoma BRAF status through ddPCR of cfDNA
|
Passby, L.
|
|
|
30 |
S7 |
p. vii15
|
artikel
|
| 16 |
Assessments of cancer-free lymph nodes for the prediction of disease progression
|
Grigoriadis, A.
|
|
|
30 |
S7 |
p. vii28
|
artikel
|
| 17 |
Association of metastatic pattern and molecular status in metastatic lung non-small cell lung cancer adenocarcinomas
|
Dormieux, A.
|
|
|
30 |
S7 |
p. vii14
|
artikel
|
| 18 |
Association of rs363293 single nucleotide polymorphism in promoter region of miRNA-143/145 with susceptibility to colorectal cancer and with patients’ outcome
|
Mihaylova, G.M.
|
|
|
30 |
S7 |
p. vii32
|
artikel
|
| 19 |
A 19-year retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration
|
Bryer, E.
|
|
|
30 |
S7 |
p. vii31
|
artikel
|
| 20 |
Cancer Research UK
|
|
|
|
30 |
S7 |
p. viii
|
artikel
|
| 21 |
Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers
|
Vanacker, H.
|
|
|
30 |
S7 |
p. vii23
|
artikel
|
| 22 |
Circulating miR-652-3p as a biomarker of drug resistance in metastatic colorectal cancer patients
|
Hedayat, S.
|
|
|
30 |
S7 |
p. vii4
|
artikel
|
| 23 |
Circulating tumour associated cells in esophageal cancers are resistance educated per previous chemo treatments
|
Limaye, S.
|
|
|
30 |
S7 |
p. vii14
|
artikel
|
| 24 |
Circulating tumour cells mRNA in treatment strategy for melanoma
|
Abramov, A.
|
|
|
30 |
S7 |
p. vii20
|
artikel
|
| 25 |
Clinical application of routine comprehensive tumour molecular profiling in the management of cancer patients
|
Mileyko, V.
|
|
|
30 |
S7 |
p. vii29
|
artikel
|
| 26 |
Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial
|
Kreutzfeldt, S.
|
|
|
30 |
S7 |
p. vii6
|
artikel
|
| 27 |
C-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer
|
Wood, G.E.
|
|
|
30 |
S7 |
p. vii20
|
artikel
|
| 28 |
CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations
|
Castillo, J.
|
|
|
30 |
S7 |
p. vii9
|
artikel
|
| 29 |
Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer
|
Martins, F.C.
|
|
|
30 |
S7 |
p. vii10-vii11
|
artikel
|
| 30 |
Combination treatment of astragalus membranaceus, dose-modified chemotherapy, and anti-PD1 checkpoint inhibitor for patients of advanced malignancy with initial cachexia or poor performance status: A single-institute experience
|
Lai, H.C.
|
|
|
30 |
S7 |
p. vii25
|
artikel
|
| 31 |
Community-driven development of a modified progression-free survival ratio for precision oncology trials
|
Mock, A.
|
|
|
30 |
S7 |
p. vii28
|
artikel
|
| 32 |
Comparative study of RT-qPCR- and NGS- based platforms for circulating human microRNA biomarker detection
|
Gargiuli, C.
|
|
|
30 |
S7 |
p. vii30
|
artikel
|
| 33 |
Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours
|
Nosková, H.
|
|
|
30 |
S7 |
p. vii28-vii29
|
artikel
|
| 34 |
Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium
|
Horak, P.
|
|
|
30 |
S7 |
p. vii24
|
artikel
|
| 35 |
Comprehensive genomic profiling and outcomes among metastatic melanoma patients (pts) treated with first-line cancer immunotherapy (CIT) in a real-world setting
|
Sadetsky, N.
|
|
|
30 |
S7 |
p. vii2
|
artikel
|
| 36 |
Concordance between tissue analysis (TA) and liquid biopsy (LB) for RAS/BRAF and the optimization of its clinical application in such a heterogeneous tumour
|
Grilo, I.
|
|
|
30 |
S7 |
p. vii29
|
artikel
|
| 37 |
Contrasting the drivers of response to immunotherapy across solid tumour types: Results from analysis of > 1000 cases
|
Litchfield, K.
|
|
|
30 |
S7 |
p. vii3
|
artikel
|
| 38 |
Copy number variations in critical cell-signalling genes with potential targeted therapeutic application
|
Nikolova, E.
|
|
|
30 |
S7 |
p. vii33
|
artikel
|
| 39 |
Correlation of MRI derived parameters and SUV uptake obtained from FDG- PET-CT with human papillomavirus status in oropharyngeal squamous cell carcinomas
|
Goyal, S.
|
|
|
30 |
S7 |
p. vii34
|
artikel
|
| 40 |
Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Updated results of an observational study
|
Kastrisiou, M.
|
|
|
30 |
S7 |
p. vii13
|
artikel
|
| 41 |
Customized hepatocellular carcinoma prediction panel
|
Abramov, A.
|
|
|
30 |
S7 |
p. vii20
|
artikel
|
| 42 |
Detecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer
|
Meng, P.
|
|
|
30 |
S7 |
p. vii7
|
artikel
|
| 43 |
Detection of actionable variants in various cancer types reveals value of whole-genome sequencing over in-silico whole-exome and hotspot panel sequencing
|
Ramarao-Milne, K.P.
|
|
|
30 |
S7 |
p. vii33
|
artikel
|
| 44 |
Detection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers
|
Mosele, F.
|
|
|
30 |
S7 |
p. vii27
|
artikel
|
| 45 |
Distribution of somatic mutations in PIK3CA gene in breast colorectal and colorectal Czech cancer patients - selected colorectal cancer patients with angiogenesis inhibitors treatment
|
Simova, J.
|
|
|
30 |
S7 |
p. vii26
|
artikel
|
| 46 |
Drug Index
|
|
|
|
30 |
S7 |
p. vii36
|
artikel
|
| 47 |
Dual MGMT inactivation by promoter hypermethylation and loss of chromosome 10q as relevant prognostic marker in glioblastoma
|
Tachon, G.
|
|
|
30 |
S7 |
p. vii5-vii6
|
artikel
|
| 48 |
Dynamics of ctDNA in patients with NSCLC
|
Zhabina, A.S.
|
|
|
30 |
S7 |
p. vii22
|
artikel
|
| 49 |
Editorial board
|
|
|
|
30 |
S7 |
p. ii-iii
|
artikel
|
| 50 |
Encyclopedic tumour analysis (ETA) guided combination regimens of hormone receptor antagonists with other systemic agents for treatment of refractory cancers
|
Vaid, A.
|
|
|
30 |
S7 |
p. vii30
|
artikel
|
| 51 |
Encyclopedic tumour analysis guided treatments with conventional drugs outperform available alternatives in refractory cancers
|
Crook, T.
|
|
|
30 |
S7 |
p. vii27-vii28
|
artikel
|
| 52 |
EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe
|
de Rojas, T.
|
|
|
30 |
S7 |
p. vii34-vii35
|
artikel
|
| 53 |
Epithelial-mesenchymal transition of tumour buds: A histopathological parameter with potential implication in oncological therapy of colorectal carcinoma
|
Jung, I.
|
|
|
30 |
S7 |
p. vii26
|
artikel
|
| 54 |
Evaluation of miRNA-135a and miRNA-9 as prognostic markers in breast cancer patients
|
Gamea, M.M.
|
|
|
30 |
S7 |
p. vii21
|
artikel
|
| 55 |
Evaluation of mouse polyclonal antibody against nNav1.5 to recognize nNav1.5 protein in human breast cancer cells using fluorescence immunostaining
|
Mokhtar, N.F.
|
|
|
30 |
S7 |
p. vii18
|
artikel
|
| 56 |
Exploration of biologic significances and mechanisms of combined atorvastatin with PI3K/Akt inhibitor in radiotherapy of colorectal cancer
|
Cheng, C.H.
|
|
|
30 |
S7 |
p. vii26-vii27
|
artikel
|
| 57 |
Exploring the role of the DDB2 protein as a potent molecular target in pancreatic ductal adenocarcinoma
|
Gilson, P.
|
|
|
30 |
S7 |
p. vii12
|
artikel
|
| 58 |
Feasibility of precision cancer medicine in advanced gynaecologic cancers
|
Taghizadeh, H.
|
|
|
30 |
S7 |
p. vii7
|
artikel
|
| 59 |
100,000 genomes project: Integrating whole genome sequencing (WGS) data into clinical practice
|
Sosinsky, A.
|
|
|
30 |
S7 |
p. vii1
|
artikel
|
| 60 |
Genomic profiling of non-oncogene-addicted aNSCLC using liquid biopsy. A single institution Italian experience
|
Di Liello, R.
|
|
|
30 |
S7 |
p. vii6
|
artikel
|
| 61 |
HER2 Ile655Val polymorphism, EGFR expression and cellular proliferation in urinary bladder carcinomas
|
Dumitru, M.
|
|
|
30 |
S7 |
p. vii22
|
artikel
|
| 62 |
Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience
|
Grilo, I.T.
|
|
|
30 |
S7 |
p. vii17
|
artikel
|
| 63 |
Identification of tamoxifen-resistant microRNA expression profiles in breast cancer: En route to precision medicine through establishing new biomarkers
|
Andreeva, O.E.
|
|
|
30 |
S7 |
p. vii19
|
artikel
|
| 64 |
Immune checkpoint molecule V-set Ig domain-containing 4 (VSIG4) expression is associated with poor prognosis in advanced gastric cancer patients
|
Kim, S-W
|
|
|
30 |
S7 |
p. vii25
|
artikel
|
| 65 |
Impact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs)
|
Scholl, S.
|
|
|
30 |
S7 |
p. vii4-vii5
|
artikel
|
| 66 |
Improving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures
|
Schulze, M.
|
|
|
30 |
S7 |
p. vii21
|
artikel
|
| 67 |
Investigating the role of chromosomal instability in immune cell activation
|
Sokac, M.
|
|
|
30 |
S7 |
p. vii25-vii26
|
artikel
|
| 68 |
Investigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC
|
Stepanova, M.
|
|
|
30 |
S7 |
p. vii16
|
artikel
|
| 69 |
JAK3 defines a unique molecular subtypes of East Asian non-small cell lung cancer patients
|
Xu, C.
|
|
|
30 |
S7 |
p. vii6-vii7
|
artikel
|
| 70 |
Large scale functional characterization of mutations and their susceptibility to targeted therapy
|
Barbash, Z.
|
|
|
30 |
S7 |
p. vii34
|
artikel
|
| 71 |
Leukotriene B4 receptors abnormal gene expression is associated with either shorter or longer survival in breast cancer patients depending on the intrinsic tumour molecular subtype
|
Kalinkin, A.I.
|
|
|
30 |
S7 |
p. vii17
|
artikel
|
| 72 |
Likelihood of targeted therapy recommendations for advanced solid tumours
|
Taghizadeh, H.
|
|
|
30 |
S7 |
p. vii29
|
artikel
|
| 73 |
LIMCH1-related genes demonstrate different invasive potential of morphological structures of breast cancer
|
Tashireva, L.
|
|
|
30 |
S7 |
p. vii16
|
artikel
|
| 74 |
Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer
|
Hockings, H.A.
|
|
|
30 |
S7 |
p. vii8
|
artikel
|
| 75 |
Ly6G+ cells in irradiated tumour tissue promote glioblastoma cell dedifferentiation and tumour recurrence
|
Seo, S.
|
|
|
30 |
S7 |
p. vii23
|
artikel
|
| 76 |
Magnetic nanovector for the down regulating CD44 and imaging of microRNA34a
|
Lee, H.
|
|
|
30 |
S7 |
p. vii23
|
artikel
|
| 77 |
Mechanistic insight into anti-cancer activity of plumbagin in endocrine resistant and HER2-overexpressed breast cancer cells
|
Sakunrangsit, N.
|
|
|
30 |
S7 |
p. vii5
|
artikel
|
| 78 |
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage
|
Lampis, A.
|
|
|
30 |
S7 |
p. vii5
|
artikel
|
| 79 |
Molecular Analysis for Personalised Therapy (MAP) 2019 Officers and Organisation
|
|
|
|
30 |
S7 |
p. ix-x
|
artikel
|
| 80 |
Molecular determinants of interaction between glioblastoma CD133+ cancer stem cells and extracellular matrix
|
Bryukhovetskiy, I.S.
|
|
|
30 |
S7 |
p. vii4
|
artikel
|
| 81 |
Molecular: Genetic analysis of uterine carcinosarcomas
|
Levitskaya, N.
|
|
|
30 |
S7 |
p. vii22-vii23
|
artikel
|
| 82 |
mTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers
|
Crook, T.
|
|
|
30 |
S7 |
p. vii32
|
artikel
|
| 83 |
NGS-based multi-gene panel analysis in early-onset colorectal cancer patients
|
Zhunussova, G.
|
|
|
30 |
S7 |
p. vii16-vii17
|
artikel
|
| 84 |
Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in pancreatic cancers
|
Chroscicki, P.
|
|
|
30 |
S7 |
p. vii18
|
artikel
|
| 85 |
Nrf2 expression in surgically resected lung adenocarcinomas: Its association with clinicopathologic features and driver oncogene alterations
|
Takamochi, K.
|
|
|
30 |
S7 |
p. vii19
|
artikel
|
| 86 |
Overexpression of EGFR, COX2 and p53 in oral squamous cell carcinoma patients of Pakistan and correlation with prognosis
|
Ali, S.M.A.
|
|
|
30 |
S7 |
p. vii21-vii22
|
artikel
|
| 87 |
Pan-cancer analysis for oncogenes and mechanisms of their upregulation
|
Dmitriev, A.A.
|
|
|
30 |
S7 |
p. vii32
|
artikel
|
| 88 |
Pan-genome cfDNA methylation analysis of metastatic prostate cancer
|
Wu, A.
|
|
|
30 |
S7 |
p. vii1
|
artikel
|
| 89 |
Patient-derived organoid models of metastatic colorectal cancer to study response to PIK3CA inhibitors
|
Barros Silva, J.D.
|
|
|
30 |
S7 |
p. vii26
|
artikel
|
| 90 |
Patterns of N-cadherin (N-cad) and vimentin (Vim) expression as a sign of epithelial-mesenchymal transition (EMT) in prostate cancer (PCa)
|
Puchinskaya, M.
|
|
|
30 |
S7 |
p. vii11
|
artikel
|
| 91 |
Plasma ctDNA RAS mutation analysis by digital polymerase chain reaction in patients with inoperable pancreatic cancer
|
Gkoura, S.
|
|
|
30 |
S7 |
p. vii12
|
artikel
|
| 92 |
Plasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial
|
Jayaram, A.K.
|
|
|
30 |
S7 |
p. vii3-vii4
|
artikel
|
| 93 |
PLSCR1 and XKR8: New markers for low-grade glioma progression and outcome
|
Havrysh, K.V.
|
|
|
30 |
S7 |
p. vii15
|
artikel
|
| 94 |
Potentially actionable mutations in intrahepatic cholangiocarcinoma
|
Frega, G.
|
|
|
30 |
S7 |
p. vii19-vii20
|
artikel
|
| 95 |
Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies
|
Johnson, Z.
|
|
|
30 |
S7 |
p. vii27
|
artikel
|
| 96 |
Prediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy
|
Moiseenko, F.
|
|
|
30 |
S7 |
p. vii13
|
artikel
|
| 97 |
Prevalence of homologous recombination deficiency (HRD)-related signatures indicates that a wider range of prostate cancer patients may benefit from PARP-inhibitor therapy
|
Sztupinszki, Z.
|
|
|
30 |
S7 |
p. vii14
|
artikel
|
| 98 |
Prognostic role of APOBEC3 genes mRNA expression in lower grade glioma
|
Ismaeil, K.
|
|
|
30 |
S7 |
p. vii12-vii13
|
artikel
|
| 99 |
Protein interactome network analysis predicts novel breast cancer candidate genes with molecular signatures
|
Peer Mohammed, M.
|
|
|
30 |
S7 |
p. vii10
|
artikel
|
| 100 |
Radiation-induced change of PD-1/PD-L1 immune checkpoint in mouse colon cancer models
|
Lim, Y.J.
|
|
|
30 |
S7 |
p. vii24
|
artikel
|
| 101 |
Results of a first panTRK IHC ringtrial
|
De Winne, K.
|
|
|
30 |
S7 |
p. vii11
|
artikel
|
| 102 |
Retrospective study evaluating the impact of genomic profiling on management of patients with metastatic breast cancer
|
Amin, A.A.
|
|
|
30 |
S7 |
p. vii21
|
artikel
|
| 103 |
RNAi and CRISPR/Cas9-based screens identify mismatch repair genes involved in platinum chemoresistance
|
Zawadzki, P.
|
|
|
30 |
S7 |
p. vii31
|
artikel
|
| 104 |
Role of immune checkpoint inhibitors in bone sarcomas and future aspects
|
Mishra, A.N.
|
|
|
30 |
S7 |
p. vii34
|
artikel
|
| 105 |
Role of molecular markers in glioblastoma patients of Pakistan
|
Mirza, Y.
|
|
|
30 |
S7 |
p. vii18-vii19
|
artikel
|
| 106 |
Role of RNF144B in triple negative breast cancer proliferation
|
Altarjami, L.
|
|
|
30 |
S7 |
p. vii19
|
artikel
|
| 107 |
Signal: The home page of mutational signatures
|
Shooter, S.
|
|
|
30 |
S7 |
p. vii33
|
artikel
|
| 108 |
Table of Contents
|
|
|
|
30 |
S7 |
p. iv
|
artikel
|
| 109 |
Targeted high-throughput sequencing for somatic mutations identification in thyroid cancer management
|
Yakushina, V.
|
|
|
30 |
S7 |
p. vii13
|
artikel
|
| 110 |
Targeted proximity ligation assays combined with sequencing for robust detection of translocations in FFPE samples
|
Feitsma, H.
|
|
|
30 |
S7 |
p. vii31-vii32
|
artikel
|
| 111 |
Targeting EGFR exon 20 insertions in non-small cell lung cancer by exploiting a dependency on parallel SRC signalling
|
Vyse, S.
|
|
|
30 |
S7 |
p. vii3
|
artikel
|
| 112 |
Temporal dissection of altered pathways during the evolution of cancer
|
Ahrenfeldt, J.
|
|
|
30 |
S7 |
p. vii1
|
artikel
|
| 113 |
Tepotinib inhibits the epithelial-mesenchymal transition and tumour growth of gastric cancers via decreasing MUC5B, MMP7, and COX2
|
Zang, D.Y.
|
|
|
30 |
S7 |
p. vii10
|
artikel
|
| 114 |
The different prognostic impact of age according to individual molecular subtypes in breast cancer
|
Eom, Y.H.
|
|
|
30 |
S7 |
p. vii7
|
artikel
|
| 115 |
The European Society for Medical Oncology (ESMO)
|
|
|
|
30 |
S7 |
p. vi
|
artikel
|
| 116 |
The importance of p53 signaling pathway in the evolution of gastric cancer
|
Gurzu, S.
|
|
|
30 |
S7 |
p. vii11
|
artikel
|
| 117 |
The properties of mitochondria in glioma stem cells
|
Hong, N.
|
|
|
30 |
S7 |
p. vii14-vii15
|
artikel
|
| 118 |
Therapeutic implications of MTH1 inhibitor TH1579 in cutaneous malignant melanoma
|
Das, I.
|
|
|
30 |
S7 |
p. vii8
|
artikel
|
| 119 |
Translational Research Index
|
|
|
|
30 |
S7 |
p. vii37-vii38
|
artikel
|
| 120 |
Tumour cells mirror embryonic developmental programs to acquire invasive and metastatic capabilities
|
Saghafinia, S.
|
|
|
30 |
S7 |
p. vii2
|
artikel
|
| 121 |
Unicancer
|
|
|
|
30 |
S7 |
p. vii
|
artikel
|
| 122 |
Using global DNA-methylation and metabolome profiles to classify variants of unknown significance (VUS) in phaeochromocytoma and paraganglioma tumours
|
Williams, S.T.
|
|
|
30 |
S7 |
p. vii5
|
artikel
|
| 123 |
Using single cell data to validate the cellular origins of a clonal expression biomarker in lung cancer
|
Biswas, D.
|
|
|
30 |
S7 |
p. vii2
|
artikel
|
| 124 |
Validation and implementation of a bespoke pan-cancer NGS panel for FFPE solid tumour analysis within an NHS setting
|
Roberts, H.
|
|
|
30 |
S7 |
p. vii25
|
artikel
|
| 125 |
ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition
|
Valiente, F.G.
|
|
|
30 |
S7 |
p. vii16
|
artikel
|
Tijdschrift beschrijving